Tauriga Sciences, Inc. Completes $225,000 Private Placement With New York City Based Institutional I
( " Tauriga" or the " Company"), a life sciences company creating a diversified portfolio of medical technology assets, novel medical devices and consumer healthcare, is pleased to announce that the Company has completed a $ 225,000 financi   08:26 May 24, 2013

Opexa Therapeutics, Inc. [OPXA] to Ring The NASDAQ Stock Market Closing Bell
[ OPXA], a biotechnology company developing TcelnaTM, a patient specific T-cell immunotherapy for the treatment of multiple sclerosis ( MS), will visit the NASDAQ MarketSite in Times Square.   07:07 May 24, 2013

Momenta Pharmaceuticals to Webcast Presentations at Two Upcoming Investor Conferences
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA.   13:38 May 23, 2013

Vical Appoints Richard M. Beleson and Stephen A. Sherwin, M.D., to Board of Directors
These risks and uncertainties include whether Vical or others will continue development of Allovectin &# xAE;, CMV or HSV-2 vaccines, or any other product candidates; whether Allovectin &# xAE;, CMV or HSV-2 vaccines, or any other product c   13:06 May 23, 2013

Repligen CEO to Present at Jefferies 2013 Global Healthcare Conference
Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs.   10:52 May 23, 2013

AIBioTech(R) Receives Subcontract Award From DynPort Vaccine Company LLC, for Continued Development
RICHMOND, Va., May 23, 2013 ( GLOBE NEWSWIRE)- AIBioTech is pleased to announce receipt of a firm fixed price subcontract from DynPort Vaccine Company LLC ( DVC), a CSC company, valued at nearly $ 3 million for laboratory studies to support   06:52 May 23, 2013

Apricus Biosciences Prices $17.1 Million Public Offering of Common Stock and Warrants
This press release contains forward-looking statements, including statements related to Apricus Biosciences, Inc.', s public offering of common stock and warrants, the anticipated use of proceeds and the timing for completion of the offerin   06:26 May 23, 2013

Lpath Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP
Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the outcome of the Phase 1 clinical trial may not be predi   06:06 May 23, 2013

Chembio Awarded $750,000 Cooperative Research Agreement
Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. &# xA0; Forward-looking statements include statements regarding the intent, belief or   05:52 May 23, 2013

Stemline Therapeutics Announces Exercise of Option to Purchase Additional Shares
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells ( CSCs) as well as the tumor bulk.   05:38 May 23, 2013

Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exem
CAMBRIDGE, Mass., May 23, 2013 ( GLOBE NEWSWIRE)- Merrimack Pharmaceuticals, Inc. announced today that the last patient has been enrolled in a Phase 2 randomized, double blind clinical trial of MM-121 in combination with exemestane in postm   05:06 May 23, 2013

Galena Biopharma to Present at the 2013 Marcum MicroCap Conference
LAKE OSWEGO, Ore., May 23, 2013 ( GLOBE NEWSWIRE)- Galena Biopharma, a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Rosemar   04:06 May 23, 2013

FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleeding
THE WOODLANDS, Texas, May 22, 2013 ( GLOBE NEWSWIRE)- Repros Therapeutics Inc. &# xAE; today announced it has met with the FDA regarding the clinical development of Proellex-V, the vaginally administered product, in the treatment of uterine   17:06 May 22, 2013

Chembio Appoints Sharon Klugewicz as Chief Operating Officer
Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. &# xA0; Forward-looking statements include statements regarding the intent, belief or   13:26 May 22, 2013

...

News Copyright © 2006 Interest!ALERT